Clinical Research Study for Adolescents with Schizophrenia

Clinical Trial Title

A Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial to Evaluate the Efficacy of Brexpiprazole Monotherapy for the Treatment of Adolescents (13-17 years old) with Schizophrenia

National Clinical Trial Number:

NCT03198078

Clinical Trial Protocol Description:

The goal of this clinical research study is to evaluate the efficacy and safety of an investigational medication for the treatment of schizophrenia in adolescents. The investigational medication has been approved by the United States Food and Drug Administration for the treatment of adult schizophrenia, and as an adjunctive treatment for major depressive disorder in adults.

Subjects have the option to enroll into a long-term, open-label-extension study after study completion.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Are an adolescent, 13-17 years of age.
  • Have a diagnoses of, or symptoms of, schizophrenia for at least 6 months.
  • Have been responsive to antipsychotic treatment (other than clozapine).
  • Have a history of relapse or exacerbation of symptoms when not receiving antipsychotic treatment.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Adrienne Adams, MD

Contact Information

Rachel Gordon, Study Coordinator